Broker recommendations for Sanofi
The Sanofi stock is rated at 1.391304 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 8 October, 2020 by a total of 23 brokers. This means that the consensus of the 23 different brokers is leaning toward to buy/moderate buy.
Sell
0 (0%) Underweight
0 (0%) Hold
8 (34.78%) Overweight
2 (8.7%) Buy
13 (56.52%)
Price target by analysts
The 20 latest analyst estimates, per Saturday 17 October, 2020, show the following high, low and average price targets.
Target Average: 61.78 USD
Target High: 69.15 USD
Target Low: 50.2 USD
Enoxaparin Sodium Market Inclined to Deliver Positive Growth Results until 2025 With Key Players| Sanofi, Sanodz, Themis Medicare Limited
Monday, 19 October 2020, 18:10:04
The research study covers the current scenario and growth prospects of the Enoxaparin Sodium market (2020-2025) according to the analysis . This study includes a extensive analysis of the key segments of the industry and also the regional analysis that
— OpenPR
Eczema Therapeutics Market 2020-28 advance research lead towards gigantic hike| Bausch Health Companies, Bayer AG, Eli Lilly, Encore Dermatology, LEO Pharma AS, Mylan NV, Pfizer, and Sanofi
Monday, 19 October 2020, 14:57:49
Eczema is a term for a group of conditions that make your skin inflamed or irritated. The most common type is atopic dermatitis or atopic eczema. “Atopic” refers to a person’s tendency to get allergic conditions such as asthma and
— OpenPR
COVID-19 tracker: J&J, BMS and AbbVie drugs pegged for NIH trial; Russia greenlights remdesivir to treat COVID-19
Friday, 16 October 2020, 21:30:00
The NIH picked drugs from J&J, BMS and AbbVie for a phase 3 trial in hospitalized patients. Russia approved remdesivir to treat COVID-19. Sanofi’s partnership exec isn’t sweating the lack of in-person meetings during the pandemic. Beckman Coulter is developing a childhood COVID-19 test, and Cue Health won a DOD contract to scale diagnostic production.
— FiercePharma
Sanofi’s mRNA Vaccine for Coronavirus to Enter Clinical Stage
Friday, 16 October 2020, 19:01:05
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
— Yahoo Finance
Rotavirus Prophylaxis Market Current and Future Trend Scenario Explored In New Latest Research Report| Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc, Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd
Friday, 16 October 2020, 15:40:20
The company profiles of all the major market players and brands that are dominating the Rotavirus Prophylaxis Market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR
— OpenPR
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.
